市场调查报告书
商品编码
1451617
2024-2032 年按技术、应用、产品、样本、最终用户和地区分類的循环肿瘤细胞市场报告Circulating Tumor Cells Market Report by Technology, Application, Product, Specimen, End User, and Region 2024-2032 |
2023年,全球循环肿瘤细胞(CTC)市场规模达到118亿美元。展望未来, IMARC Group预计到2032年市场规模将达到261亿美元,2024-2032年复合年增长率(CAGR)为8.9%。
循环肿瘤细胞(CTC)是从原发肿瘤中分裂出来并以单一单位或簇的形式出现在循环系统中的癌细胞。它们具有不同的生物学表型,例如上皮型、间质型和上皮-间质混合型。患者血液中的 CTC 水平可以早期发现癌症并作为预后指标。由于 CTC 的数量很少,因此采用了多种技术来分离、富集和检测 CTC,例如免疫捕获、基于大小的分离、基于密度的分离和显微镜检查。它在液体活检、癌症研究、药物开发和临床生物标记方面也有广泛的应用。
由于遗传性疾病、饮酒量增加和生活方式的快速改变,癌症盛行率不断上升,是推动市场成长的关键因素。 CTC 有助于肺癌、乳腺癌、消化道癌和前列腺癌的早期识别和即时监测。与此一致的是,CTC 在患者转移筛检和新抗癌药物临床前研究的使用不断增加,有利于市场成长。此外,对微创 (MI) 诊断程序的需求不断增长,以及基于 CTC 的液体活检的广泛采用,以实现快速康復和限制创伤,这为市场成长提供了相当大的推动力。除此之外,引入奈米技术来提高 CTC 分离和检测的灵敏度和效率也为市场成长提供了动力。此外,医学研究中越来越多地利用细胞培养模型来开发用于药物筛选、疾病建模、基因组编辑和肿瘤免疫的细胞培养模型,这为市场创造了积极的前景。此外,医疗保健专业人员和患者对早期癌症诊断重要性的认识不断提高,对市场成长产生了积极影响。其他因素,包括生物医学影像和生物工程技术的快速进步、广泛的研发(R&D)活动以及对预防医学和伴随诊断不断增长的需求,预计将推动市场成长。
The global circulating tumor cells (CTC) market size reached US$ 11.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 26.1 Billion by 2032, exhibiting a growth rate (CAGR) of 8.9% during 2024-2032.
Circulating tumor cells (CTC) are cancer cells that split away from the primary tumor and appear in the circulatory system as singular units or clusters. They have different biological phenotypes, such as epithelial, mesenchymal, and mixed epithelial-mesenchymal. CTC levels in a patient's blood can allow early detection of cancer and act as a prognostic indicator. As they are in minimal quantity, several technologies are used for the isolation, enrichment, and detection of CTC, such as immunocapture, size-based separation, density-based separation, and microscopy. It also has wide-ranging applications in liquid biopsy, cancer research, drug development, and clinical biomarkers.
The increasing prevalence of cancer due to genetic disorders, rising alcohol consumption, and rapid lifestyle changes are key factors driving the market growth. CTC assists in the early identification and real-time monitoring of lung, breast, digestive tract, and prostate cancer. In line with this, the increasing utilization of CTC in patient screening for metastasis and preclinical studies of new cancer drugs is favoring the market growth. Furthermore, the growing demand for minimally invasive (MI) diagnostic procedures and widespread adoption of CTC-based liquid biopsy to enable rapid recovery and limit trauma are providing a considerable boost to the market growth. Apart from this, the introduction of nanotechnology to improve the sensitivity and efficiency of CTC isolation and detection is providing an impetus to market growth. Moreover, increasing utilization in medical research to develop cell culture models for drug screening, disease modeling, genome editing, and tumor immunity is creating a positive outlook for the market. Additionally, the increasing awareness amongst healthcare professionals and patients about the importance of early cancer diagnosis is positively influencing the market growth. Other factors, including rapid advancements in biomedical imaging and bioengineering technology, extensive research and development (R&D) activities, and the rising demand for preventive medicine and companion diagnostics, are anticipated to drive the market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global circulating tumor cells (CTC) market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on technology, application, product, specimen and end user.
CTC Detection and Enrichment Method
CTC Direct Detection Methods
CTC Analysis
Clinical/Liquid Biopsy
Risk Assessment
Screening and Monitoring
Research
Cancer Stem Cell and Tumorigenesis Research
Drug/Therapy Development
Kits and Reagents
Blood Collection Tubes
Devices and Systems
Blood
Bone Marrow
Other Body Fluids
Hospital and Clinics
Research and Academic Institutes
Diagnostic Centres
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being BioFluidica Inc, Creatv MicroTech Inc., CytoLumina Technologies Corp., Fluxion Biosciences Inc., Greiner Bio-One International GmbH, Ikonisys Inc, Menarini Silicon Biosystems, Miltenyi Biotec, Qiagen N.V, Rarecells Diagnostics and Stemcell Technologies.